Immunocore (IMCR) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Syndax Pharmaceuticals (SNDX) has outperformed Immunocore (IMCR) over the past year, gaining 2.4% versus a loss of 14.4%. Over five years, SNDX leads with a -9.1% price change compared with -23.4% for IMCR. Syndax Pharmaceuticals is the larger company by market cap ($1.51 billion vs $1.50 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMCR | SNDX |
|---|---|---|
| Share price | $29.09 | $16.90 |
| Market cap | $1.50B | $1.51B |
| 1-day change | -1.09% | -0.76% |
| YTD return | -16.19% | -19.56% |
| 1-year return | -14.42% | +2.42% |
| 5-year return | -23.45% | -9.09% |
| EPS (TTM) | $-0.36 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.72 | $25.59 |
| 52-week low | $27.56 | $12.99 |
| Distance from 52-week high | -28.55% | -33.96% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +115.64% | +122.19% |
| Average volume | 443.48K | 1.55M |
| Shares outstanding | 51.50M | 89.30M |
| Employees | 524 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SNDX has outperformed IMCR by 16.8 percentage points over the past year.
About Immunocore
IMCR stock →Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 524 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
IMCR vs SNDX FAQ
Which is bigger, Immunocore or Syndax Pharmaceuticals?
Syndax Pharmaceuticals (SNDX) is larger, with a market capitalization of $1.51B compared with $1.50B for Immunocore (IMCR).
Which stock has performed better over the past year, IMCR or SNDX?
SNDX returned +2.42% over the past 12 months, compared with -14.42% for IMCR (price return, excluding dividends). Past performance does not predict future results.
Are Immunocore and Syndax Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Immunocore and Biotechnology: Pharmaceutical Preparations for Syndax Pharmaceuticals.